Lurbinectedin Active in BRCA1/2-Mutated Advanced Breast Cancer

Patients with advanced breast cancer who carry germline mutations in BRCA1/2 genes are highly sensitive to DNA damage due to deficiencies in homologous recombination repair (HRR) mechanisms. Lurbinectedin, an analog of the DNA damaging agent trabectedin, is a selective inhibitor of the transcription of protein-coding genes that results in accumulation of double-strand DNA breaks. In […]

Read More

Three Articles Worth Reading

ASCO Guidelines on HPV Testing in Head and Neck Cancer. The American Society for Clinical Oncology (ASCO) released a guideline endorsement for the College of American Pathologists guidelines surrounding human papillomavirus (HPV) testing in patients with head and neck cancers. The new guidelines call for HPV testing for all newly diagnosed squamous cell oropharyngeal cancers […]

Read More

Fatal Toxicity Associated With Immune Checkpoint Inhibitors

Immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have become an essential component of cancer treatment, and in many tumors, are now considered the standard of care. Because of their mechanism of action, these agents are associated with a unique adverse event (AE) profile driven by immunologic activation. While most immune related adverse events […]

Read More

Early Evidence of Activity of Trabectedin and Olaparib in Sarcoma

Bone and soft tissue sarcomas comprise a group of biologically diverse tumors that are associated with poor prognosis, despite an increasing number of treatment options that include chemotherapy and targeted therapy. Trabectedin is a safe and effective second-line therapy approved for treatment of advanced soft tissue sarcoma (STS). Poly(ADP ribose) polymerase (PARP) inhibitors are a […]

Read More

Immune Checkpoint Inhibitors Effective in BRAF-Mutant NSCLC

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have become standard first-line therapy for patients with advanced non-small cell lung cancer (NSCLC), but only for patients without activating mutations in EGFR or ALK, as tumors harboring these alterations do not respond well to immunotherapy. In recent years, BRAF-mutated NSCLC has emerged as a recognized molecular subtype […]

Read More

Sequential Brentuxiamb Vedotin For Hodgkin Lymphoma in the Elderly

Outcomes of patients with advanced Hodgkin lymphoma over the age of 60 tend to be inferior compared to younger patients.  One major challenge in treating this patient population is their generally poor health and inability to tolerate toxic chemotherapy regimens. Single-agent therapy with antibody-drug conjugate brentuximab vedotin (BV) has been shown to be an effective […]

Read More

Baseline steroids

Baseline Steroids Diminish Benefits of PD-(L)1 Blockade in NSCLC

Immunotherapy with PD-1 and PD-L1 immune checkpoint inhibitors has become the standard of care in patients with non-small cell lung cancer (NSCLC) who do not express targetable alterations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), or ROS1 translocation/rearrangements. Because these agents function by stimulating the immune response, use of immunosuppressive […]

Read More

Dual HER2 Blockade and AI for HER2+/HR+ Advanced Breast Cancer

Treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor (HR)-positive advanced breast cancer is challenging because bidirectional cross talk between the estrogen receptor and HER2 can lead to the development of resistance to both hormonal and anti-HER2 therapy. In these patients, adding anti-HER2 to aromatase inhibitor (AI) therapy demonstrated improved […]

Read More

PET May Predict Long-Term Benefit With Anti-PD-1 Therapy in Melanoma

PD-1 targeting immune checkpoint inhibitors have revolutionized treatment of metastatic melanoma, resulting in long-term survival in many patients. However, there are few reliable predictors of long-term response to anti-PD-1 therapy in these patients. Currently, complete response (CR) by computed tomography (CT) imaging is considered the best indicator for long-term outcomes, and it appears that these […]

Read More

Nivolumab ± Ipilimumab Effective for Refractory Esophagogastric Cancer

There are few therapeutic options for patients with metastatic chemotherapy refractory esophagogastric cancer, and prognosis for these patients is poor. Immunotherapy with PD-1 targeting immune checkpoint inhibitors has been shown to be a highly effective treatment option across a variety of solid tumors. Preclinical and early clinical data support the role for immune checkpoint blockade […]

Read More